Cargando…

Unexpected rapid increase in bone mineral density by bisphosphonate therapy after multiple spinal fractures: a case report

BACKGROUND: Osteoporosis is a serious disease that causes bone fragility fractures and increases mortality. Bisphosphonates are the first-line drugs for osteoporosis. However, the gains in bone mineral density by use of bisphosphonates alone are limited. CASE PRESENTATION: We describe the clinical o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koiwai, Hidefumi, Kamimura, Mikio, Takahashi, Jun, Nakamura, Yukio, Kato, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743166/ https://www.ncbi.nlm.nih.gov/pubmed/31514730 http://dx.doi.org/10.1186/s13256-019-2219-0

Ejemplares similares

Adequate nutrition status important for bone mineral density improvement in a patient with anorexia nervosa
por: Nakamura, Yukio, et al.
Publicado: (2018)

Pretreatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy
por: Kamimura, Mikio, et al.
Publicado: (2018)

Denosumab significantly improves lumbar spine bone mineral density more in treatment-naïve than in long-term bisphosphonate-treated patients
por: Suzuki, Takako, et al.
Publicado: (2018)

Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis
por: Kamimura, Mikio, et al.
Publicado: (2019)

Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients
por: Kamimura, M., et al.
Publicado: (2016)

Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment
por: Nakamura, Yukio, et al.
Publicado: (2018)

Short-term bisphosphonate treatment reduces serum 25(OH) vitamin D(3) and alters values of parathyroid hormone, pentosidine, and bone metabolic markers
por: Kamimura, Mikio, et al.
Publicado: (2017)

A Case with Atypical Clinical Course Diagnosed as Osteoarthritis, Osteonecrosis, Subchondral Insufficiency Fracture, or Rapidly Destructive Coxopathy
por: Nakamura, Yukio, et al.
Publicado: (2014)

Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study
por: Nakamura, Yukio, et al.
Publicado: (2015)

Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis
por: Suzuki, Takako, et al.
Publicado: (2018)

Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates
por: Kaneko, Tetsuya, et al.
Publicado: (2019)

Joint Pain Undergoes a Transition in Accordance with Signal Changes of Bones Detected by MRI in Hip Osteoarthritis
por: Kamimura, Mikio, et al.
Publicado: (2013)

Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment
por: Nakamura, Yukio, et al.
Publicado: (2017)

Bone alterations are associated with ankle osteoarthritis joint pain
por: Nakamura, Yukio, et al.
Publicado: (2016)

The Pathophysiology of Primary Hip Osteoarthritis may Originate from Bone Alterations
por: Kamimura, Mikio, et al.
Publicado: (2013)

Strontium ranelate effect on bone mineral density is modified by previous bisphosphonate treatment
por: Brun, Lucas R, et al.
Publicado: (2014)

Effects of Bisphosphonate Therapy on Bone Mineral Density in Boys with Duchenne Muscular Dystrophy
por: Ronsley, Rebecca, et al.
Publicado: (2020)

Monthly minodronate inhibits bone resorption to a greater extent than does monthly risedronate
por: Kamimura, Mikio, et al.
Publicado: (2016)

Total Hip Bone Mineral Density as an Indicator of Fracture Risk in Bisphosphonate‐Treated Patients in a Real‐World Setting
por: Banefelt, Jonas, et al.
Publicado: (2021)

Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis
por: Suzuki, Takako, et al.
Publicado: (2018)

The Pathophysiology and Progression of Hip Osteoarthritis Accompanied with Joint Pain are Potentially Due to Bone Alterations - Follow-up Study of Hip OA Patients
por: Kamimura, Mikio, et al.
Publicado: (2014)

Comparison in bone turnover markers during early healing of femoral neck fracture and trochanteric fracture in elderly patients
por: Ikegami, Shota, et al.
Publicado: (2009)

Knee Joint Pain Potentially Due to Bone Alterations in a Knee Osteoarthritis Patient
por: Komatsu, Masatoshi, et al.
Publicado: (2014)

Effects of a 'Drug Holiday' on Bone Mineral Density and Bone Turnover Marker During Bisphosphonate Therapy
por: Kong, Sung Yeol, et al.
Publicado: (2013)

Vitamin D and Calcium Addition during Denosumab Therapy over a Period of Four Years Significantly Improves Lumbar Bone Mineral Density in Japanese Osteoporosis Patients
por: Suzuki, Takako, et al.
Publicado: (2018)

Efficacy of denosumab therapy for neurofibromatosis type 1 with osteoporosis and history of fractures: a case report
por: Uehara, Masashi, et al.
Publicado: (2018)

Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates
por: Heckman, George A, et al.
Publicado: (2002)

Comparison of the efficacy of three once-weekly bisphosphonates on bone mineral density gains in Korean women
por: Lee, Ji Hyun, et al.
Publicado: (2013)

Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women
por: Augoulea, A., et al.
Publicado: (2017)

Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis
por: Arends, Suzanne, et al.
Publicado: (2020)

Early Changes in Bone Specific Turnover Markers During the Healing Process After Vertebral Fracture
por: Hashidate, Hiroyuki, et al.
Publicado: (2011)

Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients
por: Suzuki, Takako, et al.
Publicado: (2017)

Associations of self-reported height loss and kyphosis with vertebral fractures in Japanese women 60 years and older: a cross-sectional survey
por: Kamimura, Mikio, et al.
Publicado: (2016)

Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study
por: Flodin, Lena, et al.
Publicado: (2014)

Efficacy and Safety of Bisphosphonates for Low Bone Mineral Density After Kidney Transplantation: A Meta-Analysis
por: Kan, Shun-Li, et al.
Publicado: (2016)

Difference in Bone Mineral Density Change at the Lateral Femoral Cortices according to Administration of Different Bisphosphonate Agents
por: Kim, Sungjun, et al.
Publicado: (2016)

Risk factors of adjacent vertebral collapse after percutaneous vertebroplasty for osteoporotic vertebral fracture in postmenopausal women
por: Takahara, Kenji, et al.
Publicado: (2016)

Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
por: Uehara, Masashi, et al.
Publicado: (2021)

Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data
por: Bell, Katy J L, et al.
Publicado: (2009)

Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition
por: Van Poznak, Catherine
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_bvvha7o2bmu2taiteuktjhdd03